BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 15, 2004
 |  BioCentury  |  Strategy

Whetting pharma's appetite

Early Bird Dealmaking

Whetting pharma's appetite

Though deals for late stage products promise a more timely impact on earnings, the need for innovation remains urgent for pharma licensing specialists, who say they are willing to pay more for earlier technology because the quality of biotech R&D is increasing.

Indeed, Merck & Co. Inc., AstraZeneca plc (LSE:AZN; AZN, London, U.K.) and GlaxoSmithKline plc (LSE:GSK; GSK, London, U.K.) have been relatively active over the past year or so, doing multiple discovery through Phase II deals to complement and bolster their own R&D engines.

In addition to doing several reformulation deals, GSK has added two Phase I compounds to its HIV...

Read the full 528 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >